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After 30 years of treatment with Mectizan (ivermectin), cutaneous and ocular complications of Onchocerca
volvulus infection are now scarce in endemic communities. Indeed, transmission has been interrupted and the
O. volvulus- associated disease has disappeared in some African foci. Despite this success, onchocerciasis
elimination in Loa loa co-endemic areas is still constrained by severe adverse events (SAEs) occurring after
ivermectin treatment in some individuals harbouring very high L. loa microﬁlaremia. One approach towards
the prevention of these SAEs is to identify individuals with high L. loa microﬁlaremia and exclude them from
ivermectin treatment. The development of the LoaScope has provided the tool that underlies this test and not
treat (TaNT) strategy. The ﬁrst successful TaNT campaign was conducted in a L. loa highly endemic focus in
Cameroon in 2015 without any SAEs. To accomplish this within a research setting, 60 people were deployed
for this campaign, making this ‘research’ strategy not sustainable from a cost perspective. We describe here a
way of reducing the cost of the TaNT strategy with a smaller team (three people) selected within affected
communities. We also suggest the organization of a TaNT campaign in affected countries.
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Introduction
In 1987, the donation of the safe anthelminthic ivermectin
(Mectizan) for control of the disease caused by Onchocerca
volvulus dramatically changed the ﬁght against onchocerciasis
and set the stage for other control programmes. In 1996, the
Community-Directed Treatment with Ivermectin (CDTI) strategy
developed by the African Programme for Onchocerciasis Control
(APOC) resulted in signiﬁcant improvement in the treatment
coverage for mass drug administration (MDA) in Africa. After 30
years of MDA with Mectizan, the skin and ocular diseases asso-
ciated with onchocerciasis are now only infrequently seen in
most endemic communities because of this sustained annual
treatment.1,2 Onchocerciasis transmission has been interrupted
in some African foci thanks to either once- or twice-a-year
mass administration of ivermectin.3–5 The success of the CDTI
strategy has provided convincing evidence of the possibility to
move from control of disease to elimination of this infection
from Africa,6 leading the APOC to shift its goal from control to
complete elimination.7
Despite the success of the onchocerciasis MDA-based pro-
gramme and the paradigm shift from control to elimination, an
important challenge appears in Loa loa co-endemic areas, with
potential life-threatening (occasionally fatal) severe adverse
events (SAEs) occurring after ivermectin in those few individuals
harbouring very high L. loa microﬁlarial densities (>30 000 micro-
ﬁlariae [mf]/mL of blood).8 As regards the high burden of oncho-
cerciasis as well as the important socio-economic impact, and
the fact that only those few individuals (<5%) harbouring very
high L. loa microﬁlarial densities are likely to experience SAEs, it
was considered that the beneﬁts of treating highly endemic
onchocerciasis outweigh the consequences related to SAEs. Mass
treatments have therefore been conducted in loiasis-endemic
areas under a surveillance system to closely follow up and man-
age individuals experiencing SAEs following ivermectin treatment
in meso- and hyperendemic onchocerciasis foci. This heightened
surveillance strategy has been somewhat effective in alleviating
the communities’ concerns. Despite these efforts, treatment
coverage is commonly low in these co-endemic areas and indivi-
duals refusing treatment, so-called systematic non-compliers,
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continue to host O. volvulus, the causative agent of onchocercia-
sis, and thus contribute to ongoing transmission.
In addition to the fear of ivermectin treatment and the con-
stitution of systematic non-compliers, maintaining active trans-
mission, ivermectin mass administration against hypo-endemic
onchocerciasis was not recommended in loiasis co-endemic
areas as a consequence of an unfavourable beneﬁt–risk ratio.
Two main approaches have been initiated to avoid the occur-
rence of these speciﬁc SAEs. The ﬁrst approach was the utiliza-
tion of a ‘pretreatment drug’ that could safely lower the L. loa
parasitemia of heavily infected individuals to below the accept-
able microﬁlarial density threshold prior to administration of
ivermectin. To this end, low doses of ivermectin, albendazole,
mebendazole and various antimalarial drugs have been unsuc-
cessfully tried.9–16
The second approach was to develop a system to identify indi-
viduals at risk of post-ivermectin SAEs (i.e., those with L. loa mf
levels of ≥30 000 mf/mL). To do this, an innovative, user-friendly
diagnostic tool, the LoaScope, was developed for the rapid diag-
nosis of these ‘at-risk’ individuals17 and a new so-called test and
not treat (TaNT) strategy was developed and implemented for the
ﬁrst time in Cameroon in 2015 and 2017.18
The pilot phase of the TaNT strategy
The pilot phase of the TaNT approach was ﬁrst implemented in
the Okola Health District in Cameroon, where treatments had
been halted in 1999 as a consequence of SAEs that had
occurred after the ﬁrst CDTI campaign. The campaign was organ-
ized in four phases: the census; community and individual sensi-
tization; tests and treatments; and AE surveillance (Figure 1).
During two TaNT campaigns, conducted in 2015 and 2017, nearly
37 500 individuals were tested and about 36 600 were treated
with ivermectin. Importantly, no SAEs were recorded during these
two TaNT campaigns.18,19
Despite this success, all the TaNT-related activities (census,
sensitization, tests and treatments, AE surveillance) were con-
ducted by central teams made up of researchers, graduate stu-
dents and other technical and specialized staff (lab technicians,
consultants, etc.). About 30 students were recruited for the cen-
sus and supervised by a researcher. The sensitization team con-
sisted of two individuals who spoke the local language,
supported by a driver. Five teams were dedicated to the TaNT
exercise itself. Each team was made up of one supervisor, two
recorders (one collecting data on individual forms and the other
recording data on an electronic tablet), a local community
member to assist in translation and three laboratory personnel
(one for blood sampling, one for making the calibrated thick
blood smears and one to use the LoaScope). Finally, there was
also a healthcare professional (nurse or medical doctor), who
was assisted by a local community drug distributor (CDD)
(Figure 1). After treatment, patients were closely monitored for
AEs by the two AE surveillance teams, each made up of a driver
and a physician.
Although the cost study of these two campaigns is ongoing,
the pilot phase of the TaNT strategy was costly and hardly
extendable to other settings similar to the Okola Health District
(hypo-endemic for onchocerciasis and endemic for loiasis) in
Cameroon and Central Africa. It therefore appears urgent to
translate this successful interventional project into an oper-
ational activity that is sustainable.
Translating the TaNT strategy into ﬁeld
operations
Translation of the TaNT strategy into ﬁeld operations was inspired by
the CDTI strategy, which had been quite successful. The CDTI strat-
egy relies on the endemic communities themselves to conduct the
MDA under the supervision of the local health system. Thus the
treatment of a speciﬁc community is organized and conducted with
the participation of the entire community. The CDDs for each village
are selected by the local authorities and the population. These local
staff conduct a census and communicate with the national health
authorities to ensure that sufﬁcient drugs are provided according to
the number of eligible residents requiring MDA treatment.
In the operationalization plan, a CDD is necessary and will be
chosen from among community members, as done in the clas-
sic CDTI strategy. This CDD will be trained to conduct the census,
perform sensitization and administer ivermectin treatment. In
addition to the CDD with the same prerogatives and job descrip-
tion as in the classic CDTI strategy, a testing team (blood drawer
and LoaScope operator [LoaScopist]) will be needed to conduct
the LoaScope tests and to deﬁne eligibility for ivermectin treat-
ment. Regarding the proﬁles of these personnel, we thought
that the blood drawer could be an assistant nurse or an assist-
ant lab technician (who could be recruited from the area’s
healthcare community, private health facilities or the many
training schools that exist in different health districts) and the
LoaScopist could just be a literate individual from the commu-
nity since the LoaScope is a user-friendly tool.
The deployment of such a community-based TaNT strategy in
the ﬁeld will be aligned and based on the experience of the classic
CDTI strategy. First, meetings for advocacy will be organized
regarding the voluntary aspect of involvement in this activity.
The training will be done in a staggered manner, aligning
with the health pyramid. In general, the health pyramid is made
Figure 1. Organization of the TaNT team and the ﬂow of participants
during the research phase.
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up of three levels: a central level encompassing the Ministry of
Health, which oversees disease-speciﬁc programmes, and gen-
eral and reference hospitals; an intermediate level involving the
regional/provincial Delegations of Health and the regional/pro-
vincial hospital; and a peripheral level with Health District (HD)
(or health zone) services and HD hospitals. Within the HD (or
health zone), there are health areas comprised of communities.
The health centre lies at the centre of the health area. The
national manager of the onchocerciasis (or onchocerciasis and
lymphatic ﬁlariasis [LF] or neglected tropical disease [NTD],
according to the country) programme and their technical staff,
as well as the regional delegates and the technical staff in
charge of NTDs, should be briefed on the TaNT strategy, the shift
from control to elimination of onchocerciasis, use of the
LoaScope, the surveillance and management of AEs, and the
diagnosis and management of SAEs. This training should be
done by the TaNT expert team. The teams at all levels will also
be trained in basic maintenance of the LoaScope.
After training at the national/regional level, training should be
continued, using the same agenda, at the HD level. In the ﬁrst
year it is probably optimal that the regional (intermediate) level
and the TaNT expert teams train the HD and health area staff. In
subsequent years, the training could be done by intermediate-
level staff, supervised by the onchocerciasis (or onchocerciasis-LF
or NTD) programme manager and his technical team.
A sensitization campaign should be carried out in all HDs eli-
gible to implement the TaNT strategy to inform the residents
about the programme. The campaign should focus on details con-
cerning the diseases (onchocerciasis, LF and loiasis), their conse-
quences and their treatment. Emphasis should also be placed on
the possible AEs that can occur after ivermectin treatment and
contrast this with the important fact that with the new TaNT strat-
egy there should be no resulting SAEs. The TaNT strategy should
be organized at the district level. In each community, one member
(the CDD) will be selected to take care of an average of 100 inha-
bitants (20 households). This selection will be organized by local
authorities and the CDD should be designated by the area popula-
tion. The CDD will be trained as stated above to conduct the cen-
sus and administer treatment (dosage of ivermectin according to
patient height). He/she will also be trained in the indications and
contraindications of ivermectin and albendazole administration,
patient registration and completion of the treatment report. The
head of the health centre will select an assistant nurse or assist-
ant lab technician, or any other health personnel who will be
trained to collect blood samples for the LoaScope and a literate
community member will receive training on use of the LoaScope.
An operational TaNT team will be deployed in three to ﬁve com-
munities, depending on the size of the communities, to reduce
the distances covered by each team (Figure 2). Following train-
ing, the CDDs will organize the census, then the nurse and the
TaNT teams will plan and organize treatments. For the ﬁrst year,
the TaNT teams will start in contiguous areas to facilitate super-
vision by the head of the health centre. The health area could be
split into two zones, with the ﬁrst half of the health area starting
in the ﬁrst week, followed by the other half in the second week.
The treatments in the overall health area should be supervised
by the HD team.
Considering that this strategy cannot be deployed following a
door-to-door strategy, the TaNT team will organize the procedures
in the community so as to shorten the distance between the
households and treatment points; for example, arrangements
could be made for villagers to join neighbouring treatment sites if
this is more practical for them. The treatment activities should
start at 10:00 h (to take into account the diurnal periodicity of L.
loa mf) and, depending on the number of inhabitants to be trea-
ted at a particular site, the team will stay at each site for 1 or 2 h
before moving on to the next treatment site. In subsequent years,
the CDD will register and treat directly (without LoaScope examin-
ation) all the populations that were tested and treated the ﬁrst
year, as L. loa microﬁlaremia is reduced by 90% the year following
the ﬁrst treatment with ivermectin.20 The LoaScope tests will be
done in those who have never been tested previously. The follow-
up for AEs will be done in the same manner as indicated in the
Mectizan Expert Committee/Technical Consultative Committee
guidelines.21
It will be important to have technical support always available
at the national level that can address the concerns of the TaNT
teams in the ﬁeld. The technical support team will be fully access-
ible to help solve any technical problems with the LoaScope and
ensure maintenance and software updates according to the man-
ufacturer’s and developer’s recommendations. Such a national-
level team should be under the direction of the national NTD pro-
gramme, thus ensuring that there is a good ﬂow of information
between the different bodies involved in NTD programme, the
Ministry of Health and supporting partners.
Pending questions and/or challenges to the
success of the operationalization plan
The ﬁrst challenge is the management of heavily infected indivi-
duals excluded from ivermectin mass administration. Those
excluded individuals will be invited to attend the health centre,
where they will undergo a test with the SD Bioline Biplex (Wb123-
and Ov16-based POC) tests for onchocerciasis and LF22 and trea-
ted accordingly (doxycycline 100mg/day for 5 weeks for O. volvulus
or albendazole every 6 months for Wuchereria bancrofti). Those
Figure 2. Core TaNT operational teams and deployment of the cam-
paign in 11 communities in a single health area.
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who are not infected by either LF or onchocerciasis will have the
opportunity to receive 200mg albendazole twice daily for 21
days14 to lower their L. loa mf load. If, during the following year’s
treatment campaign, their mf level is below the risk threshold,
they will receive ivermectin.
The second challenge is the ability of these community person-
nel to conduct this strategy. Because of the low complexity of the
strategy (as compared with other community interventions), the
strategy is likely to be successful. We really hope this system will
work, as the Community Directed Intervention Group showed that
community members could implement a signiﬁcantly more com-
plex intervention. Indeed, a large-scale study showed that the CDI
process provides an effective platform for the delivery of health
interventions in the model of core principles of primary healthcare.
Many public health interventions are now based on community
partnership. Active community participation in the organization
and delivery of interventions and a structured and systematic
partnership of communities and health systems are key factors in
the success of the interventions.23 Also, blood drawers will be
selected from among technical personnel (retired or just trained
but not yet employed by the government), and the LoaScope is a
user-friendly tool. However, we would advise that there be a tech-
nical support team to manage technical issues that may occur
during a community-based TaNT campaign.
Conclusion
The TaNT interventional project was conducted with success in
2015 and 2017 in a loiasis-endemic area, the Okola HD. Indeed,
mass ivermectin administration was conducted without a single
SAE being recorded. Despite this success, the TaNT strategy was
costly and hardly applicable in similar settings, and there was an
urgent need to develop an operational plan to deploy such a strat-
egy. We have proposed a community-based approach for the TaNT
strategy, modelled on the CDTI approach, taking into consideration
the success of the CDTI approach in improving ivermectin treat-
ment coverage and the capacity of community members in imple-
menting public health interventions. We now hope that this
community approach of the TaNT strategy will be successfully
implemented by community members and accelerate the elimin-
ation of onchocerciasis in L. loa–endemic countries of Central Africa.
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